Pathology  ||| S:0 E:10 ||| NNP
and  ||| S:10 E:14 ||| CC
epidemiology  ||| S:14 E:27 ||| NN
of  ||| S:27 E:30 ||| IN
HPV  ||| S:30 E:34 ||| NNP
infection  ||| S:34 E:44 ||| NN
in  ||| S:44 E:47 ||| IN
females  ||| S:47 E:55 ||| JJ
Human  ||| S:55 E:61 ||| JJ
papillomaviruses  ||| S:61 E:78 ||| NNS
( ||| S:78 E:79 ||| -LRB-
HPVs ||| S:79 E:83 ||| NNP
)  ||| S:83 E:85 ||| -RRB-
are  ||| S:85 E:89 ||| VBP
a  ||| S:89 E:91 ||| DT
large  ||| S:91 E:97 ||| JJ
family  ||| S:97 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
small  ||| S:107 E:113 ||| JJ
double-stranded  ||| S:113 E:129 ||| JJ
DNA  ||| S:129 E:133 ||| NN
viruses  ||| S:133 E:141 ||| NN
that  ||| S:141 E:146 ||| IN
infect  ||| S:146 E:153 ||| JJ
squamous  ||| S:153 E:162 ||| JJ
epithelia ||| S:162 E:171 ||| NN
.  ||| S:171 E:173 ||| .
It  ||| S:173 E:176 ||| PRP
has  ||| S:176 E:180 ||| VBZ
been  ||| S:180 E:185 ||| VBN
established  ||| S:185 E:197 ||| VBN
that  ||| S:197 E:202 ||| IN
infection  ||| S:202 E:212 ||| NN
with  ||| S:212 E:217 ||| IN
specific  ||| S:217 E:226 ||| JJ
HPV  ||| S:226 E:230 ||| NN
types  ||| S:230 E:236 ||| NNS
is  ||| S:236 E:239 ||| VBZ
a  ||| S:239 E:241 ||| DT
contributing  ||| S:241 E:254 ||| JJ
factor  ||| S:254 E:261 ||| NN
to  ||| S:261 E:264 ||| TO
different  ||| S:264 E:274 ||| JJ
types  ||| S:274 E:280 ||| NNS
of  ||| S:280 E:283 ||| IN
anogenital  ||| S:283 E:294 ||| JJ
cancer ||| S:294 E:300 ||| NN
,  ||| S:300 E:302 ||| ,
including  ||| S:302 E:312 ||| VBG
vulval ||| S:312 E:318 ||| NN
,  ||| S:318 E:320 ||| ,
vaginal ||| S:320 E:327 ||| JJ
,  ||| S:327 E:329 ||| ,
anal ||| S:329 E:333 ||| NN
,  ||| S:333 E:335 ||| ,
penile ||| S:335 E:341 ||| NN
,  ||| S:341 E:343 ||| ,
and  ||| S:343 E:347 ||| CC
head  ||| S:347 E:352 ||| NN
and  ||| S:352 E:356 ||| CC
neck  ||| S:356 E:361 ||| NN
cancers ||| S:361 E:368 ||| NNS
.  ||| S:368 E:370 ||| .
Approximately  ||| S:370 E:384 ||| RB
4 ||| S:384 E:385 ||| CD
%  ||| S:385 E:387 ||| NN
of  ||| S:387 E:390 ||| IN
all  ||| S:390 E:394 ||| DT
cancers  ||| S:394 E:402 ||| NNS
are  ||| S:402 E:406 ||| VBP
associated  ||| S:406 E:417 ||| VBN
with  ||| S:417 E:422 ||| IN
HPV ||| S:422 E:425 ||| NNP
.  ||| S:425 E:427 ||| .
HPV  ||| S:427 E:431 ||| NNP
infection  ||| S:431 E:441 ||| NN
is  ||| S:441 E:444 ||| VBZ
the  ||| S:444 E:448 ||| DT
major  ||| S:448 E:454 ||| JJ
cause  ||| S:454 E:460 ||| NN
of  ||| S:460 E:463 ||| IN
cervical  ||| S:463 E:472 ||| JJ
cancer  ||| S:472 E:479 ||| NN
and  ||| S:479 E:483 ||| CC
genital  ||| S:483 E:491 ||| JJ
warts ||| S:491 E:496 ||| NNS
.  ||| S:496 E:498 ||| .
Genital  ||| S:498 E:506 ||| NNP
HPV  ||| S:506 E:510 ||| NNP
infections  ||| S:510 E:521 ||| NNS
are  ||| S:521 E:525 ||| VBP
very  ||| S:525 E:530 ||| RB
common ||| S:530 E:536 ||| JJ
,  ||| S:536 E:538 ||| ,
are  ||| S:538 E:542 ||| VBP
sexually  ||| S:542 E:551 ||| RB
transmitted ||| S:551 E:562 ||| VBN
,  ||| S:562 E:564 ||| ,
and  ||| S:564 E:568 ||| CC
have  ||| S:568 E:573 ||| VB
a  ||| S:573 E:575 ||| DT
peak  ||| S:575 E:580 ||| NN
prevalence  ||| S:580 E:591 ||| NN
between  ||| S:591 E:599 ||| IN
ages  ||| S:599 E:604 ||| CD
18  ||| S:604 E:607 ||| CD
and  ||| S:607 E:611 ||| CC
30 ||| S:611 E:613 ||| CD
.  ||| S:613 E:615 ||| .
Most  ||| S:615 E:620 ||| JJS
of  ||| S:620 E:623 ||| IN
these  ||| S:623 E:629 ||| DT
infections  ||| S:629 E:640 ||| JJ
clear  ||| S:640 E:646 ||| JJ
spontaneously ||| S:646 E:659 ||| NN
,  ||| S:659 E:661 ||| ,
but  ||| S:661 E:665 ||| CC
in  ||| S:665 E:668 ||| IN
10-20 ||| S:668 E:673 ||| CD
%  ||| S:673 E:675 ||| NN
of  ||| S:675 E:678 ||| IN
women ||| S:678 E:683 ||| NNS
,  ||| S:683 E:685 ||| ,
these  ||| S:685 E:691 ||| DT
infections  ||| S:691 E:702 ||| NNS
remain  ||| S:702 E:709 ||| VBP
persistent  ||| S:709 E:720 ||| JJ
and  ||| S:720 E:724 ||| CC
are  ||| S:724 E:728 ||| VBP
at  ||| S:728 E:731 ||| IN
risk  ||| S:731 E:736 ||| NN
of  ||| S:736 E:739 ||| IN
progression  ||| S:739 E:751 ||| VBG
to  ||| S:751 E:754 ||| TO
grade  ||| S:754 E:760 ||| CD
2 ||| S:760 E:761 ||| CD
/ ||| S:761 E:762 ||| CD
3  ||| S:762 E:764 ||| CD
cervical  ||| S:764 E:773 ||| FW
intraepithelial  ||| S:773 E:789 ||| FW
neoplasm  ||| S:789 E:798 ||| FW
( ||| S:798 E:799 ||| -LRB-
CIN ||| S:799 E:802 ||| NNP
)  ||| S:802 E:804 ||| -RRB-
and  ||| S:804 E:808 ||| CC
eventually  ||| S:808 E:819 ||| RB
to  ||| S:819 E:822 ||| TO
invasive  ||| S:822 E:831 ||| VB
cancer  ||| S:831 E:838 ||| NN
of  ||| S:838 E:841 ||| IN
the  ||| S:841 E:845 ||| DT
cervix  ||| S:845 E:852 ||| NN
( ||| S:852 E:853 ||| -LRB-
ICC ||| S:853 E:856 ||| NNP
) ||| S:856 E:857 ||| -RRB-
.  ||| S:857 E:859 ||| .
CINs  ||| S:859 E:864 ||| NNS
are  ||| S:864 E:868 ||| VBP
genetically  ||| S:868 E:880 ||| RB
unstable  ||| S:880 E:889 ||| JJ
lesions  ||| S:889 E:897 ||| NNS
with  ||| S:897 E:902 ||| IN
a  ||| S:902 E:904 ||| DT
30-40 ||| S:904 E:909 ||| JJ
%  ||| S:909 E:911 ||| NN
risk  ||| S:911 E:916 ||| NN
of  ||| S:916 E:919 ||| IN
progression  ||| S:919 E:931 ||| VBG
to  ||| S:931 E:934 ||| TO
ICC ||| S:934 E:937 ||| NNP
.  ||| S:937 E:939 ||| .
If  ||| S:939 E:942 ||| IN
left  ||| S:942 E:947 ||| JJ
untreated ||| S:947 E:956 ||| NN
,  ||| S:956 E:958 ||| ,
they  ||| S:958 E:963 ||| PRP
form  ||| S:963 E:968 ||| VBP
a  ||| S:968 E:970 ||| DT
spectrum  ||| S:970 E:979 ||| NN
of  ||| S:979 E:982 ||| IN
increasing  ||| S:982 E:993 ||| VBG
cytological  ||| S:993 E:1005 ||| JJ
atypia ||| S:1005 E:1011 ||| NN
,  ||| S:1011 E:1013 ||| ,
ranging  ||| S:1013 E:1021 ||| VBG
from  ||| S:1021 E:1026 ||| IN
low-grade  ||| S:1026 E:1036 ||| JJ
CIN1  ||| S:1036 E:1041 ||| NN
to  ||| S:1041 E:1044 ||| TO
high-grade  ||| S:1044 E:1055 ||| JJ
CIN3 ||| S:1055 E:1059 ||| NN
;  ||| S:1059 E:1061 ||| :
the  ||| S:1061 E:1065 ||| DT
latter  ||| S:1065 E:1072 ||| NN
are  ||| S:1072 E:1076 ||| VBP
caused  ||| S:1076 E:1083 ||| VBN
almost  ||| S:1083 E:1090 ||| RB
exclusively  ||| S:1090 E:1102 ||| RB
by  ||| S:1102 E:1105 ||| IN
high-risk  ||| S:1105 E:1115 ||| JJ
HPVs ||| S:1115 E:1119 ||| NN
,  ||| S:1119 E:1121 ||| ,
HPV  ||| S:1121 E:1125 ||| NNP
16  ||| S:1125 E:1128 ||| CD
and  ||| S:1128 E:1132 ||| CC
18 ||| S:1132 E:1134 ||| CD
.  ||| S:1134 E:1136 ||| .
Infection  ||| S:1136 E:1146 ||| NN
with  ||| S:1146 E:1151 ||| IN
HPV  ||| S:1151 E:1155 ||| NNP
requires  ||| S:1155 E:1164 ||| VBZ
a  ||| S:1164 E:1166 ||| DT
microabrasion  ||| S:1166 E:1180 ||| NN
in  ||| S:1180 E:1183 ||| IN
the  ||| S:1183 E:1187 ||| DT
genital  ||| S:1187 E:1195 ||| JJ
epithelium ||| S:1195 E:1205 ||| NN
.  ||| S:1205 E:1207 ||| .
The  ||| S:1207 E:1211 ||| DT
oncogenic  ||| S:1211 E:1221 ||| JJ
properties  ||| S:1221 E:1232 ||| NNS
of  ||| S:1232 E:1235 ||| IN
high-risk  ||| S:1235 E:1245 ||| JJ
HPV  ||| S:1245 E:1249 ||| NNP
reside  ||| S:1249 E:1256 ||| NN
in  ||| S:1256 E:1259 ||| IN
the  ||| S:1259 E:1263 ||| DT
E6  ||| S:1263 E:1266 ||| NNP
and  ||| S:1266 E:1270 ||| CC
E7  ||| S:1270 E:1273 ||| CD
genes ||| S:1273 E:1278 ||| NNS
,  ||| S:1278 E:1280 ||| ,
which  ||| S:1280 E:1286 ||| WDT
if  ||| S:1286 E:1289 ||| IN
inappropriately  ||| S:1289 E:1305 ||| RB
expressed  ||| S:1305 E:1315 ||| VBN
in  ||| S:1315 E:1318 ||| IN
dividing  ||| S:1318 E:1327 ||| VBG
cells  ||| S:1327 E:1333 ||| NNS
deregulate  ||| S:1333 E:1344 ||| JJ
cell  ||| S:1344 E:1349 ||| NN
division  ||| S:1349 E:1358 ||| NN
and  ||| S:1358 E:1362 ||| CC
differentiation ||| S:1362 E:1377 ||| NN
.  ||| S:1377 E:1379 ||| .
HPV  ||| S:1379 E:1383 ||| NNP
DNA  ||| S:1383 E:1387 ||| NNP
testing  ||| S:1387 E:1395 ||| NN
has  ||| S:1395 E:1399 ||| VBZ
been  ||| S:1399 E:1404 ||| VBN
shown  ||| S:1404 E:1410 ||| VBN
consistently  ||| S:1410 E:1423 ||| RB
to  ||| S:1423 E:1426 ||| TO
be  ||| S:1426 E:1429 ||| VB
superior  ||| S:1429 E:1438 ||| JJ
to  ||| S:1438 E:1441 ||| TO
cytology  ||| S:1441 E:1450 ||| VB
in  ||| S:1450 E:1453 ||| IN
terms  ||| S:1453 E:1459 ||| NNS
of  ||| S:1459 E:1462 ||| IN
sensitivity  ||| S:1462 E:1474 ||| NN
and  ||| S:1474 E:1478 ||| CC
positive  ||| S:1478 E:1487 ||| JJ
predictive  ||| S:1487 E:1498 ||| JJ
value  ||| S:1498 E:1504 ||| NN
and  ||| S:1504 E:1508 ||| CC
will  ||| S:1508 E:1513 ||| MD
become  ||| S:1513 E:1520 ||| VB
a  ||| S:1520 E:1522 ||| DT
major  ||| S:1522 E:1528 ||| JJ
tool  ||| S:1528 E:1533 ||| NN
in  ||| S:1533 E:1536 ||| IN
cervical  ||| S:1536 E:1545 ||| JJ
cancer  ||| S:1545 E:1552 ||| NN
screening ||| S:1552 E:1561 ||| NN
,  ||| S:1561 E:1563 ||| ,
at  ||| S:1563 E:1566 ||| IN
least  ||| S:1566 E:1572 ||| JJS
in  ||| S:1572 E:1575 ||| IN
the  ||| S:1575 E:1579 ||| DT
developed  ||| S:1579 E:1589 ||| JJ
countries ||| S:1589 E:1598 ||| NNS
.  ||| S:1598 E:1600 ||| .
